Chimeric Receptors with 4-1BB Stimulatory Signaling Domain (SJ-03-0018)
- *Abstract
-
This invention entails a novel chimeric receptor (anti-CD19-BB-zeta) that contains an anti-CD19 single-chain variable domain, the hinge and transmembrane domains of CD8alpha, the signaling domain of CD3zeta and the intracellular signaling domain of 4-1BB. T-cells transduced with this chimeric receptor exert powerful and specific cytotoxicity against ALL cells, which is superior to that of lymphocytes with receptors lacking 4-1BB.
Key words: B-lineageacute lymphoblastic leukemia (ALL), CD19+ B-lymphoid malignancies, B-celllymphoma, T-cell receptor
Granted patents or published applications:PCTPublication No. 2005/044996
Related scientific references: Imai C, et al., "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia", Leukemia 18(4):676-684 (2004).
- Country/Region
- USA
